Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023
10 11월 2023 - 10:00PM
Business Wire
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it
will be presenting new data from its Phase 2 trials evaluating the
potential clinical impact that VIR-3434 and VIR-2218 could have for
chronic hepatitis B (CHB) and chronic hepatitis delta (CHD)
patients at the American Association for the Study of Liver
Diseases (AASLD) The Liver Meeting®, taking place in Boston, MA,
from November 10-14, 2023. These include one late-breaking poster
presentation and one late-breaking oral presentation.
Late-Breaking Presentations
- Title: VIR-2218 and VIR-3434 With or Without Pegylated
Interferon Alfa-2A for the Treatment of Chronic HBV Infection: End
of Treatment (EOT) Results After 24 Weeks of Therapy (March Study
Part B) (Abstract #48500) Session: Late Breaking Poster
Session Date: Monday, November 13 Time: 1:00 p.m. ET
Presenter: Edward Gane, M.D., Professor of Medicine at the
University of Auckland, New Zealand, and Chief Hepatologist,
Transplant Physician and Deputy Director of the New Zealand Liver
Transplant Unit at Auckland City Hospital
- Title: The Monoclonal Antibody VIR-3434 And siRNA
VIR-2218 for the Treatment of Chronic Hepatitis D Virus:
Preliminary Results from the Phase 2 SOLSTICE Trial (Abstract
#5004) Session: Oral, Late Breaking Parallel Session
Date: Monday, November 13 Time: 3:00 p.m. ET
Presenter: Tarik Asselah, M.D., Ph.D., Professor of
Hepatology at the Hôpital Beaujon, APHP, Clichy, France, and at the
University of Paris, and Head of Viral Hepatitis at INSERM UMR1149,
France
The AASLD late breaking presentation abstracts can be accessed
under Events & Presentations in the Investors section of the
Vir website here.
Vir will host an investor conference call to discuss the Phase 2
CHD & CHB AASLD data at 1:30 p.m. Pacific Time / 4:30 p.m.
Eastern Time on November 13th. A live webcast will be available on
https://investors.vir.bio and will be archived on www.vir.bio for
30 days.
About Chronic Hepatitis B Chronic hepatitis B (CHB)
infection remains an urgent global public health challenge
associated with significant morbidity and mortality. Approximately
300 million people around the world are living with CHB, and
approximately 900,000 of them die from associated complications
each year. These patients are significantly underserved by existing
therapies with low functional cure rates, lifelong daily therapy
and/or poor tolerability. Vir is working to achieve a functional
cure for the millions of people with CHB around the world through
its broad and differentiated portfolio.
About Chronic Hepatitis Delta Chronic hepatitis delta
(CHD) infection occurs as a simultaneous co-infection or
super-infection with chronic hepatitis B. An estimated 12 million
people globally are infected with CHD, representing approximately
5% of those infected with CHB. CHB-CHD co-infection is considered
the most severe form of chronic viral hepatitis due to more rapid
progression toward hepatocellular carcinoma and liver-related
death.
About VIR-3434 VIR-3434 is an investigational
subcutaneously administered antibody designed to block entry of
hepatitis B and hepatitis delta viruses into hepatocytes and to
reduce the level of virions and subviral particles in the blood.
VIR-3434, which incorporates Xencor’s Xtend™ and other Fc
technologies, has been engineered to potentially function as a T
cell vaccine against hepatitis B virus and hepatitis delta virus,
as well as to have an extended half-life. VIR-3434 was identified
using Vir’s proprietary monoclonal antibody discovery platform.
About VIR-2218 VIR-2218 is an investigational
subcutaneously administered hepatitis B virus-targeting small
interfering ribonucleic acid (siRNA) that Vir believes has the
potential to stimulate an immune response and have direct antiviral
activity against hepatitis B virus and hepatitis delta virus. It is
the first siRNA in the clinic to include Enhanced Stabilization
Chemistry Plus (ESC+) technology to enhance stability and minimize
off-target activity, which potentially could result in an increased
therapeutic index. VIR-2218 is the first asset in the Company’s
collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical
trials.
About Vir Biotechnology, Inc. Vir Biotechnology, Inc. is
an immunology company focused on combining cutting-edge
technologies to treat and prevent infectious diseases and other
serious conditions. Vir has assembled two technology platforms that
are designed to stimulate and enhance the immune system by
exploiting critical observations of natural immune processes. Its
current clinical development pipeline consists of product
candidates targeting hepatitis B and hepatitis delta viruses and
human immunodeficiency virus. Vir has several preclinical
candidates in its pipeline, including those targeting influenza A
and B, COVID-19, RSV/MPV and HPV. Vir routinely posts information
that may be important to investors on its website.
Forward-Looking Statements This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Words such as “may,”
“will,” “plan,” “potential,” “aim,” “expect,” “anticipate,”
“promising” and similar expressions (as well as other words or
expressions referencing future events, conditions or circumstances)
are intended to identify forward-looking statements. These
forward-looking statements are based on Vir’s expectations and
assumptions as of the date of this press release. Forward-looking
statements contained in this press release include, but are not
limited to, statements regarding Vir’s strategy and plans, the
potential clinical effects of VIR-3434 and VIR-2218, the potential
benefits, safety and efficacy of VIR-3434 and VIR-2218, data from
Vir’s multiple ongoing trials evaluating VIR-3434 and VIR-2218,
Vir’s plans and expectations for its HBV and HDV portfolios, and
risks and uncertainties associated with drug development and
commercialization. Many factors may cause differences between
current expectations and actual results, including unexpected
safety or efficacy data or results observed during clinical trials
or in data readouts; the occurrence of adverse safety events; risks
of unexpected costs, delays or other unexpected hurdles;
difficulties in collaborating with other companies; successful
development and/or commercialization of alternative product
candidates by Vir’s competitors; changes in expected or existing
competition; delays in or disruptions to Vir’s business or clinical
trials due to the COVID-19 pandemic, geopolitical changes
(including the war in Ukraine) or other external factors; and
unexpected litigation or other disputes. Drug development and
commercialization involve a high degree of risk, and only a small
number of research and development programs result in
commercialization of a product. Results in early-stage clinical
trials may not be indicative of full results or results from later
stage or larger scale clinical trials and do not ensure regulatory
approval. You should not place undue reliance on these statements,
or the scientific data presented. Other factors that may cause
actual results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in
Vir’s filings with the U.S. Securities and Exchange Commission,
including the section titled “Risk Factors” contained therein.
Except as required by law, Vir assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231106658171/en/
Media Carly Scaduto Senior Director, Media Relations
cscaduto@vir.bio +1-314-368-5189 Investors Sasha Damouni
Ellis Executive Vice President, Chief Corporate Affairs Officer
sdamouni@vir.bio
Vir Biotechnology (NASDAQ:VIR)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Vir Biotechnology (NASDAQ:VIR)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024